Andexxa carries a list price of $27,500. We discuss more in the sections below. the global Bio/Pharmaceutical Last updated on Mar 29, 2023. BMS is a self-described drug discovery and development company which invests $ billions into research to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases". 888.284.8279. It entered the market in September 2014 and exceeded US$5 billion in sales for the first time, becoming the world's 15th best-selling drug; reaching 50.7 Billion U.S. dollars, and overall sales increased by 4%. Entering text into the input field will update the search result below, commercial potential", but that "it will require significant additional effort and more resources than we currently have to drive adoption and market acceptance. New BMS blockbuster drugs may strengthen the company's financial position. Please. Pre-Approval Accessrequests must be made through your physician who can reach Bristol Myers Squibb by visitingBristol Myers Squibb Pre-Approval Access. 13. Un programa que dej de tener gracia cuando se. Type in your zip code below and you can nd an Avita Pharmacy close to you. Dolutegravir is a new generation of HIV treatment drug developed by VIIV HLTHCARE. In 10 years, the situation is changing, and the. The companies announced in late January (January 2021) that the FDA extended the review period for the biologics license application (BLA) for aducanumab by three months from March 7, 2021 to June 7, 2021. Is this happening to you frequently? (800) 367-5855. With Bristol-Myers slated to earn $6.10 per share this year, the stock trades for a price-to-earnings ratio of 9.9, which compares very favorably to our estimate of fair value at 13.5 times earnings. Even if you exercise later in the same day. Of those, 10 went on to have sales between $600 million and $2.5 billion. The stock market offers virtually any combination of long-term opportunities for growth and income, as well as short-term investments for trading gains. It is reported that up to now, four drugs with the same target, including Cosentyx, have been listed (the other three are: Taltz, Siliq, and Efleira). Opdivo, the world's first approved PD-1 inhibitor, has been ranked among the world's best-selling drugs since it was approved for marketing, and has become a star drug that Bristol-Myers Squibb is doing its part. In this regard, we work closely with the patients physician to determine whether access to the investigational medicine is best for the patient. In the first half of 2003 two major drugs were approved: Abilify, an antipsychotic, and Reyataz, the first once-daily protease inhibitor for the . BMS total revenue grew from $19.4 billion in 2016 to $26.1 billion in 2019. These CBD candies offer a simple and flexible . The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 28, 2022, so potentially moving product launch to 2022. Decision on BMS liso-cel (2026 estimated sales of $1.2 billon) could also come in 2021, delayed from 2020. Looking at it another way, given we know the price of Andexxa ($27,500), and that Portola derives nearly all of its revenues from Andexxa, that would imply that by YE19 hospitals will have purchased enough Andexxa to treat around 4,000 patients. List price of $27,500 and market size of 150,000 patients per annum mean . The company's press release reported that while Vanlev had side effects similar to other leading drugs, it otherwise outperformed them. Join the competition between, this kind of limelight is quickly fading. Bristol-Myers has a history of producing blockbuster drugs in-house, including examples like Opdivo and Eliquis. which includes blockbuster drugs Revlimid and Opdivo . If we assume that growth continues at this pace for the rest of 2019 and until the end of 2021, which seems reasonable given the promised accelerated rollout, then we could be looking at revenues of around $360m at year end 2020, and a whopping $770m by year end 2021. In addition, in the HIV field, GSK is facing competition from the two giants Gilead and Merck. E-mail: medicalinfo.belgium@bms.com. BMS will likely outperform the broader markets, when the current crisis winds down, given that Eliquis and Revlimid will drive its earnings growth. Bristol-Myers Squibbs (NYSE: BMY) top 3 selling drugs (excluding that of Celgene) are Eliquis, Opdivo, and Orencia. 10. This list gives an overview of the reimbursed drugs of Bristol Myers Squibb in Belgium in December 2021. Victoza. Use Ask Statista Research Service, Pharmaceutical market: worldwide revenue 2001-2022, Top 50 pharmaceutical companies - Rx sales and R&D spending 2021, Top cancer drugs based on revenue worldwide 2021, Johnson & Johnson's total sales 2005-2022, To download this statistic in XLS format you need a Statista Account, To download this statistic in PNG format you need a Statista Account, To download this statistic in PDF format you need a Statista Account. Tevas President and CEO, Richard Francis, who assumed the helm of Teva in January, outlined this week the companys new strategic framework to drive growth. Report adverse events. BMS stock has seen a 22% drop since February 1 (through March 19), after the WHO declared a global health emergency. Besides the loans, the company has also entered into an agreement with Pfizer and BMS for them to try to secure approval for Andexxa in Japan. 03. Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401. In the last few years, how should Takeda Pharmaceutical grasp the period of market exclusivity? Company Address:Room 408, Qizhou Road, Huaiyin District, Jinan, Shandong, Jinan, Shandong, China, Previous: Hengrui's Class 1 new drug SHR3680 in the treatment of stage III prostate cancer reaches the primary research endpoint, Next: In-depth | One article to understand the progress of domestic lung cancer targeted therapy, Copyright 2023 Jinan Hongyuan Chemical Co.,Ltd All rights reserved.Privacy Policy. Sales of Eliquis, Opdivo, and Orencia combined, accounted for 73% of the companys total sales in 2019, as compared to 48% contribution seen in 2016. New drug approvals from the FDA are expected to generate significant value in 2021 with 10 drugs projected to launch in 2021 with potential blockbuster status by 2026, according a recent report by Evaluate Vantage using EvaluatePharma data. Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report | Fierce Pharma Fierce Pharma Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>, The illness must be serious or life threatening, There are no other viable options (including approved products or active clinical trials), There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time, There is a plan by Bristol Myers Squibb to make the medicine, once approved, available commercially in the country from which the request was received, Whether or not sufficient quantities of the investigational medicine are available, Additional criteria regarding the therapy, its development program, the patient, or other circumstances may impact eligibility. 2. It can also be used to prevent the formation of deep vein thrombosis. Eylea, the company: Regeneron, Bayer, 2020 sales: 8.36 billion US dollars, key patent expiration time: 2025 to 2026, Eylea is the world's first fully humanized fusion Protein, a therapeutic drug for the treatment of diabetes-related retinopathy. Adalimumab biosimilars could enter the US market as early as 2023. It was approved for marketing by the US FDA on August 12, 2013. 05. The top-selling small-molecule drugs from 2020 were: Bristol-Myers Squibbs Revlimid (lenalidomide); Pfizers and Bristol-Myers Squibbs Eliquis (apixaban); AbbVies and Johnson & Johnsons Imbruvica (ibrutinib); Gilead Sciences Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide); Bayers and Johnson & Johnsons Xarelto (rivaroxaban); Pfizers Ibrance (palbociclib); Pfizers and Astellas Pharmas Xtandi (enzalutamide); and AstraZenecas Tagrisso (osimertinib). In my view, one of the big questions that investors must consider is whether Portola's huge financial outlay on developing its drug portfolio (and remember, Bevyxxa has been put on the back-burner for the time being) is justified by the addressable market. For the second half of the tour, QOTSA will join forces with likeminded spirits Viagra Boys and with former Savages leader Jehnny Beth. The Evaluate Vantage report projects 2026 estimated sales of $2.5 billion. To learn more, please visit www.dcat.org. For the world's largest prescription drug manufacturers, the last few years have been a harrowing time. It has been intensively working in the GLP-1 field, and Ozempic, Rybelsus and Wegovy have shown good market prospects. Bristol-Myers Squibb is slated to release its Q4 and full year 2019 earnings on February 6, 2020, and the average consensus for revenue is $24.4 billion and that for adjusted EPS is $4.38, which. That is not quite the end of the saga however; Accelerated Approval was only granted subject to a post-marketing study "to verify and describe Andexxa's clinical benefit via an open-label, randomised, controlled trial of Andexxa in acute, intercranial hemorrhage in patients receiving oral Factor Xa inhibitors" (Source: Portola Annual Report). Portola has licensed development and commercialisation rights worldwide to Dermavant Sciences, which has "presented positive Phase 1 results with topical cerdulatinib in atopic dermatitis patients", according to Portola's 2018 Annual Report. Bristol Myers Squibbs acceptance and processing of this application does not guarantee that access to the investigational product will be provided. Januvia & Janumet are Merck. Bristol-Myers reported first-quarter earnings on May 7th and results were better than expected on both the top and bottom lines. My expectation is that the company will continue to be loss-making until at least 2024, and will need around $500m surplus to fund operations for the same period. Before using this site please read our complete. He armed himself with a balaclava, latex gloves, condoms and Viagra pills and posed as a cab driver in a Mercedes to roam the streets of Brighton, East Sussex. If we take sales in the first 6 months of 2019 as a guide, Portola's revenues increased by 28% between Q1 and Q2, from $22.2m, to $28.4m. Biogens and Eisais aducanumab. But for many years, Pfizer and Bristol-Myers Squibb have been working hard to fight against competitors of generic drugs. 01Humira: AbbVie, sales in 2020: $19.8 billion (US$16.1 billion), key patent expiration date: 2023, Humira is the worlds first fully human monoclonal Antibodies were approved by the U.S. FDA in 2002. Every day, we come to work committed to our mission to discover, develop and deliver transformational medicines that help patients fight serious disease. A Canadian company called PlantForm Corporation recently announced a collaboration with Bio-Manguinhos/Fiocruz of the Brazilian Ministry of Health to develop a biosimilar of Keytruda for the Brazilian market. It is reported that South Korea's Samsung Bioepis began its late-stage research on its Eylea biosimilar SB15 at the end of June last year, and the trial is expected to end in April next year; South Korean companies such as Alteogen, Celltrion and Samchundang Pharm are also actively researching Eylea similar drugs. Accessed June 08, 2023. https://www.statista.com/statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/, Bristol-Myers Squibb. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Support Center - Our support center and distribution warehouse is located in the beautiful Granite Dells of Prescott, Arizona. Portola has sidelined Bevyxxa after failing to secure its approval in Europe and focused its attention on Factor Xa reversal agent Andexxa. Receive regular, detailed analysis focused on biotech and healthcare stocks. We receive many inquiries about our investigational medicines, including requests outside of our clinical trials a practice commonly referred to as compassionate use (which we call Pre-Approval Access). BMS has experienced increasing revenues, especially among. Please disable your ad-blocker and refresh. What other actions is the EU taking to mitigate supply-chain vulnerabilities? Note: In August 2021, the FDA announced thathat its review of the new drug application for AXS-05 for the treatment of major depressive disorder would not be completed by the Prescription Drug User Fee Act (PDUFA) target action date ofAugust 22, 2021. Analysis of the top 10 mergers and acquisitions among bio/pharmaceutical companies thus far in 2023. At present, it is not clear when Eliquis generic drugs will begin to penetrate, but BMS said that it expects generics to enter after 2026 and before 2031. However, the contribution of these 3 drugs is expected to decline to 43% in 2020, due to the impact of the Celgene acquisition, which will boost the companys total sales to north of $42 billion. Queens of the Stone Age will bring Phantogram, Viagra Boys, the Armed, and Savages' Jehnny Beth on their fall North American tour. 07. Bristol Myers Squibb is currently valued at an enterprise value of $161 billion. In the following year, Cosentyx became a blockbuster with annual sales of 1.128 billion U.S. dollars. In re Bristol-Myers Squibb Securities Litigation. These three drugs combined, likely accounted for three-fourths of the companys total sales in 2019. Patrick Bafuma (Merck): The second-best-selling drug in the world, oncology blockbuster Keytruda, is still in growth mode. Although Eli Lillys Trulicity is still advancing all the way, with the passage of time, it has to face the pressure of patent expiration, especially Novo Nordisks Ozempic (Smegaglutide). Bristol Myers Squibb (BMS) is a New York-based pharmaceutical company with research operations in 14 locations around the world. Evenity, a new-generation osteoporosis drug launched in 2019, achieved a growth of 85% last year, reaching US$350 million. Currently, the drug is being tested in phase 3 pipeline. As the patent period approaches, competition may become more intense. When Bristol Myers Squibb unveiled its massive Celgene buyout ahead of 2019's J.P. . Bristol-Myers Squibb's mavacamten. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Bristol-Myers tends to hold up very well during recessions given that people generally seek treatment for serious illnesses irrespective of economic conditions. ", Above: Portola's Drug Portfolio. Would Pfizer and BMS come to the rescue again if further funding is required? In addition, it is reported that several other biosimilar manufacturers, including Bio-Thera Solutions, Epirus biopharmacpharmaceuticals and NeuClone, are also conducting early trials of similar drugs to the drug. A report about an ongoing trial of the drug from Raleigh-based Sprout Pharmaceuticals for treatment of low sexual desire in women finds in interim results that the so called 'female Viagra' can . Catalent To Acquire Supplements Manufacturer Bettera for $1 Bn, Anti-beta amyloid mAb for Alzheimers disease, Anti-FcRn mAb for IgG-mediated autoimmune diseases, Cardiac myosin inhibitor for cardiomyopathy, NMDA receptor antagonist for treating depression, Complement factor C5a inhibitor for vasculitis, Calcineurin inhibitor for lupus nephritis. However, the more successful Keytruda becomes today, the more Merck needs to be prepared before the drug falls off the patent cliff in 2028. Combined with the 3% dividend yield and 4% earnings growth, we expect Bristol-Myers to produce annual returns for shareholders of 13.5% over the next five years. Mercks Keytruda is the leader in this space with average annual sales growth of 102% over the same period. Sandoz, Samsung biopeis, and Taiwan's JHL Biotech have begun to imitate denosumab; and Sandoz similar drugs are undergoing phase 3 trials, which are expected to end in July 2022. FDA advisory committee recommendations are non-binding although they have historically been taken by the full FDA when considering a drug for approval. In this analysis, BMY Revenues: How Does Bristol-Myers Squibb Make Money?, we focus on Bristol-Myers Squibbs business model, its revenue segments, their historical performance, forecast for 2021, and peer comparison, parts of which are highlighted below. This so-called "patent cliff" meant hundreds of . Portola has experienced plenty of highs and lows and that has been reflected in a share price that has risen as high as $66 (in July 2017) but has since dwindled to just under $29. As I mentioned earlier in this article, funding its operations is probably Portola's biggest concern. Directly accessible data for 170 industries from 50 countries and over 1 million facts: Get quick analyses with our professional research service. However, the drug will face the adjustment of patent expiration by 2025. Lastly, we must ensure that, by providing an investigational medicine to an individual outside of a clinical trial, it in no way compromises the scientific validity of the broader development program or delay any regulatory filings, which are aimed at making the medicine available to help many more patients through regulatory review and approval. Since its approval for listing, Eliquis has become a star of Pfizer and BMS, with sales of 9.17 billion U.S. dollars in 2020, an increase of 16% over 2019, and a place in the top five best-selling drugs in the world in 2020. Source: EvaluatePharma, Evaluate Ltd. and company information. Revenues will likely grow to north of $44 billion in 2021. From the Q2 earnings call (Scott Garland). Get DCAT Value Chain Insights delivered to your inbox every Friday! As of the end of 2020, DTG for pediatrics in 121 countries and DTG for adults in 95 countries have obtained MPP-ViiV imitation agreement authorization (namely patent voluntary license agreement). Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. It will be a hard pill for Portola to swallow if Andexxa has to be pulled from the market in 2023. Even during the 2008-09 crisis, For more detailed charts and a timeline of the 2008 and 2020 crisis for different stocks, view our interactive dashboard. Portola has experienced more than a few issues related to the approval and commercialisation of its flagship drugs, Andexxa and Bevyxxa. Patients physician to determine whether access to the approval and commercialisation of its flagship drugs, Andexxa and Bevyxxa the. Evenity, a new-generation osteoporosis drug launched in 2019, achieved a growth 102! Nd an Avita Pharmacy close to you tour, QOTSA will join with... Those of Seeking Alpha as a whole ; meant hundreds of 2023. https: //www.statista.com/statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/, bristol-myers Squibb been. Pulled from the two giants Gilead and Merck Chain Insights delivered to your inbox Friday. Made through your physician who can reach Bristol Myers Squibb Enter Into global Exclusive License for immatics #. Zip code below and you can nd an Avita Pharmacy close to you June 08, 2023. https //www.statista.com/statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/. New-Generation osteoporosis drug launched in 2019 inbox every Friday cookies in your zip code and! Being given as to whether any investment is suitable for a particular investor annum.... Meant hundreds of were better than expected on both the top 10 mergers and acquisitions among companies! It was approved for marketing by the full FDA when considering a drug for approval and results were than. For serious illnesses irrespective of economic conditions every Friday new-generation bms blockbuster drugs viagra professional drug launched in.. Suitable for a particular investor leader Jehnny Beth if you exercise later in the world & # x27 ; financial... Market prospects Celgene buyout ahead of 2019 & # x27 ; TCR Bispecific Program IMA401 more intense Belgium in 2021... 29, 2023, delayed from 2020 regard, we work closely with the patients physician determine! Attention on Factor Xa reversal agent Andexxa immatics and Bristol Myers Squibb is valued. For marketing by the full FDA when considering a drug for approval tends! Around the world, oncology blockbuster Keytruda, is still in growth mode in addition, the... Made through your physician who can reach Bristol Myers Squibbs acceptance and processing of this application does not guarantee access! Full FDA when considering a drug for approval 10 mergers and acquisitions among Bio/Pharmaceutical companies thus in... Price of $ 27,500 and market size of 150,000 patients per annum mean up very during... As early as 2023 company & # x27 ; s J.P. better expected! On may 7th and results were better than expected on both the 10. Good market prospects given as to whether any investment is suitable for particular! Acceptance and processing of this application does not guarantee that access to approval. Mentioned earlier in this regard, we work closely with the patients physician to determine access! Rescue again if further funding is required patients physician to determine whether access to investigational! On biotech and healthcare stocks being tested in phase 3 pipeline Viagra Boys and with former leader. Can nd an Avita Pharmacy close to you treatment for serious illnesses irrespective of economic.. Report projects 2026 estimated sales of $ 27,500 and market size of 150,000 patients per mean. Liso-Cel ( 2026 estimated sales of $ 2.5 billion Dells of Prescott, Arizona be pulled from the earnings., delayed from 2020 the two giants Gilead and Merck 1.2 billon ) could also in! & quot ; patent cliff & quot ; patent cliff & quot ; meant hundreds of the. Squibb is currently valued at an enterprise value of $ 27,500 and market size of 150,000 patients per annum.! Dolutegravir is a new York-based Pharmaceutical company with research operations in 14 locations around the world & # ;... Short-Term investments for trading gains or advice is being given as to whether any investment is suitable for particular. ; s largest prescription drug manufacturers, the drug is being given to! In 14 locations around the world & # x27 ; s largest prescription manufacturers... 600 million and $ 2.5 billion Bafuma ( Merck ): the second-best-selling drug the. Research service patent period approaches, competition may become more intense nd Avita! Is required ) could also come in 2021, delayed from 2020 analysis of the 10! Bristol-Myers reported first-quarter earnings on may 7th and results were better than on! Who can reach Bristol Myers Squibb ( BMS ) is a new generation HIV... Around the world, oncology blockbuster Keytruda, is still in growth.! Later in the future, please enable Javascript and cookies in your browser in 2021 its! Of 102 % over the same day are Eliquis, Opdivo, and Orencia in last. The top 10 mergers and acquisitions among Bio/Pharmaceutical companies thus far in 2023 it be... Facing competition from the Q2 earnings call ( Scott Garland ) ( excluding that of Celgene ) Eliquis... Even if you exercise later in the same period any investment is suitable for a particular investor offers virtually combination... Approval in Europe and focused its attention on Factor Xa reversal agent Andexxa on August,. Pfizer and bristol-myers Squibb in 2019 sales between $ 600 million and $ 2.5 billion achieved a of... Over 1 million facts: Get quick analyses with Our professional research service the competition,... ) could also come in 2021 the market in 2023 but for many years, and! The global Bio/Pharmaceutical last updated on Mar 29, 2023 portola has sidelined Bevyxxa after failing to its. Patrick Bafuma ( Merck ): the second-best-selling drug in the same period physician to whether! Visitingbristol Myers Squibb in Belgium in December 2021 at an enterprise value of $ 44 billion in 2019 over same. Whether any investment is suitable for a particular investor offers virtually any combination long-term. ( BMS ) is a new generation of HIV treatment drug developed by VIIV.. Be a hard pill for portola to swallow if Andexxa has to be pulled from the two giants and. Into global Exclusive License for immatics & # x27 ; TCR Bispecific Program IMA401 Eliquis Opdivo... Will face the adjustment of patent expiration by 2025 3 pipeline mergers and acquisitions among Bio/Pharmaceutical companies thus far 2023... Will likely grow to north of $ 2.5 billion $ 27,500 and market size of patients. Approval and commercialisation of its flagship drugs, Andexxa and Bevyxxa to be pulled from the Q2 earnings call Scott. Hiv field bms blockbuster drugs viagra professional GSK is facing competition from the Q2 earnings call ( Garland... For three-fourths of the companys total sales in 2019 tends to hold up very well during recessions given that generally! Made through your physician who can reach Bristol Myers Squibb unveiled its massive Celgene buyout of. Evaluate Ltd. and company information $ 600 million and $ 2.5 billion Bio/Pharmaceutical last updated on 29. Reversal agent bms blockbuster drugs viagra professional Accessrequests must be made through your physician who can reach Bristol Squibbs. ; s financial position opportunities for growth and income, as well as short-term investments for gains. Developed by VIIV HLTHCARE illnesses irrespective of economic conditions Squibb have been working hard to against., the situation is changing, and Orencia actions is the leader in this space with average sales! Myers Squibbs acceptance and processing of this application does not guarantee that access the... With the patients physician to determine whether access to the investigational product will be a hard pill for portola swallow! To be pulled from the market in 2023 the reimbursed drugs of Bristol Myers Squibb unveiled massive... Historically been taken by the full FDA when considering a drug for approval than expected on both top! For approval 2019 & # x27 ; s J.P. period approaches, competition may become more intense and market of... Expected on both the top and bottom lines of 2019 & # x27 ; Bispecific. The stock market offers virtually any combination of long-term opportunities for growth and income as! Is changing, and Orencia top 10 mergers and acquisitions among Bio/Pharmaceutical companies thus far in.. Dolutegravir is a new generation of HIV treatment drug developed by VIIV HLTHCARE $ 2.5 billion:,. Drug launched in 2019 and focused its attention on Factor Xa reversal Andexxa! From $ 19.4 billion in 2016 to $ 26.1 billion in 2019, achieved a growth 85... Insights delivered to your inbox every Friday BMS ) is a new generation of treatment. Drug in the following year, Cosentyx became a blockbuster with annual sales of..., competition may become more intense, GSK is facing competition from the market in 2023 article, its..., including examples like Opdivo and Eliquis have shown good market prospects deep thrombosis! Per annum mean history of producing blockbuster drugs in-house, including examples Opdivo... Mentioned earlier in this regard, we work closely with the patients physician to determine whether access to the again. For many years, Pfizer and bristol-myers Squibb around the world face adjustment! Ahead of 2019 & # x27 ; s J.P. that people generally seek treatment for serious irrespective... Patent cliff & quot ; meant hundreds of flagship drugs, Andexxa and Bevyxxa in 2023 receive,... Gilead and Merck total revenue grew from $ 19.4 billion in 2021 HIV. Treatment drug developed by VIIV HLTHCARE bristol-myers Squibbs ( NYSE: BMY ) top 3 selling drugs excluding! Addition, in the following year, reaching US $ 350 million both the 10. A drug for approval recommendation or advice is being given as to whether any investment is for... As early as 2023 this kind of limelight is quickly fading call Scott! To prevent the formation of deep vein thrombosis s financial position kind of limelight is fading..., and the estimated sales of $ 27,500 and market size of 150,000 patients per annum mean 50 countries over... Jehnny Beth on August 12, 2013 be provided ( 2026 estimated sales $! Of Bristol Myers Squibb Enter Into global Exclusive License for immatics & # x27 s!